T6364

Desfesoterodine (5-HMT) is a new muscarinic receptor antagonist with Kb of 0.84 nM.

CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM, demonstrating significant proliferation inhibitory activity against various cancer cell lines in vitro.

BI-4142 is an orally active, potent and selective HER2 inhibitor that inhibits cancer cell proliferation, suppresses her2-dependent cell lines and inhibits downstream signalling.

CCG-273463 is a potent, covalent, selective inhibitor of GRK5 (IC50: 9 nM). CCG-273463 can be used to study heart failure, hypertrophic cardiomyopathy and cancer.

(3S,4R)-PF-6683324 is a pro-myosin-related kinase (Trk) inhibitor with research potential for pain and cancer.

Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.

ONO-9780307 is a specific antagonist of LPA1 (lysophosphatidic acid receptor 1) (IC50: 2.7 nM).

COX-2-IN-9 is a selective, potent, orally active COX-2 inhibitor (IC50: 10.17 μM).COX-2-IN-9 has a higher COX-2 selectivity than Celecoxib.COX-2-IN-9 exhibits good in vivo anti-inflammatory activity and low ulcerogenic effect.

DCN1-UBC12-IN-1 is a potent and specific DCN1-UBC12 inhibitor with an IC50 value of 2.86 nM and anti-cardiac fibrogenic activity.

EGFR kinase inhibitor 1 is a potent inhibitor of EGFR that acts on WT (IC50: 37 nM), l885R/T790M (IC50: 1.7 nM), and L858R/T790M/C797S (IC50>300 nM). It is capable of blocking the cell cycle in G0/G1 phase, inducing apoptosis, and has an inhibitory effect on cell metastasis. Additionally, EGFR kinase inhibitor 1 exhibits anti-proliferative and anti-tumor effects.

Ned-K, a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist, exhibits inhibitory effects on myocardial ischemia and reperfusion (sIR)-induced calcium oscillations.